SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kraig Biocraft Laboratories, Inc – ‘10KSB’ for 12/31/07 – ‘EX-14.1’

On:  Wednesday, 3/26/08, at 12:49pm ET   ·   For:  12/31/07   ·   Accession #:  1213900-8-516   ·   File #:  333-146316

26 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/26/08  Kraig Biocraft Laboratories, Inc  10KSB      12/31/07    4:881K                                   Edgar Agents LLC/FA

Annual Report by a Small Business   —   Form 10-KSB
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10KSB       2007 Annual Report                                  HTML    499K 
 2: EX-14.1     Code of Ethics                                      HTML      9K 
 3: EX-31.1     Certification of Chief Executive Officer Pursuant   HTML     14K 
                          to Section 302 of the Sarbanes-Oxley Act               
                          of 2002                                                
 4: EX-32.1     Certification of Chief Executive Officer Pursuant   HTML      8K 
                          to Section 906 of the Sarbanes-Oxley Act               
                          of 2002                                                


EX-14.1   —   Code of Ethics


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C:   C: 
KRAIG BIOCRAFT LABORATORIES, INC.
FINANCIAL CODE OF ETHICS
 
As a public company, it is of critical importance that Kraig Biocraft Laboratories, Inc. (“KRAIG”) filings with the Securities and Exchange Commission be accurate and timely. Depending on their position with KRAIG, employees may be called upon to provide information to assure that KRAIG’s public reports are complete, fair, and understandable. KRAIG expects all of its employees to take this responsibility seriously and to provide prompt and accurate answers to inquiries related to KRAIG’s public disclosure requirements.
 
KRAIG’s Finance Department bears a special responsibility for promoting integrity throughout KRAIG, with responsibilities to stakeholders both inside and outside of KRAIG. The Chief Executive Officer (CEO), Chief Financial Officer (CFO), and Finance Department personnel have a special role both to adhere to the principles of integrity and also to ensure that a culture exists throughout KRAIG as a whole that ensures the fair and timely reporting of KRAIG’s financial results and conditions. Because of this special role, the CEO, CFO, and all members of KRAIG’s Finance Department are bound by KRAIG’s Financial Code of Ethics, and by accepting the Financial Code of Ethics, each agrees that they will:
 
-        Act with honesty and integrity, avoiding actual or actual conflicts of interest in personal and professional relationships.
 
-        Provide information that is accurate, complete, objective, relevant, timely and understandable to ensure full, fair, accurate, timely, and understandable disclosure in the reports and documents that KRAIG files with, or submits to, government agencies and in other public communications.
 
-        Comply with the rules and regulations of federal, state and local governments, and other appropriate private and public regulatory agencies.
 
-        Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing one’s independent judgment to be subordinated.
 
-        Respect the confidentiality of information acquired in the course of one’s work, except when authorized or otherwise legally obligated to disclose. Confidential information acquired in the course of one’s work will not be used for personal advantage.
 
-        Share job knowledge and maintain skills important and relevant to stakeholders needs.
 
-        Proactively promote and be an example of ethical behavior as a responsible partner among peers, in the work environment and in the community. 
 
-        Achieve responsible use of, and control over, all KRAIG assets and resources employed by, or entrusted to yourself, and your department.
 
-        Receive the full and active support and cooperation of KRAIG’s Officers, Sr. Staff, and all employees in the adherence to this Financial Code of Ethics.
 
-        Promptly report to the CEO or CFO any conduct believed to be in violation of law or business ethics or in violation of any provision of this Code of Ethics, including any transaction or relationship that reasonably could be expected to give rise to such a conflict. Further, to promptly report to the Chair of KRAIG ’s Audit Committee such conduct if by the CEO or CFO or if they fail to correct such conduct by others in a reasonable period of time.
 

26 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/01/24  Kraig Biocraft Laboratories, Inc. 10-K       12/31/23   75:8.1M                                   M2 Compliance LLC/FA
11/22/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. POS AM                67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 6/06/23  Kraig Biocraft Laboratories, Inc. S-1/A                 66:13M                                    M2 Compliance LLC/FA
 5/09/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/27/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.9M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. POS AM                65:9.1M                                   M2 Compliance LLC/FA
 3/29/23  Kraig Biocraft Laboratories, Inc. 10-K       12/31/22   70:8.7M                                   M2 Compliance LLC/FA
12/01/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:14M                                    M2 Compliance LLC/FA
 5/25/22  Kraig Biocraft Laboratories, Inc. S-1/A                 64:12M                                    M2 Compliance LLC/FA
 4/14/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:10M                                    M2 Compliance LLC/FA
 3/23/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.7M                                   M2 Compliance LLC/FA
 3/16/22  Kraig Biocraft Laboratories, Inc. 10-K       12/31/21   69:9.6M                                   M2 Compliance LLC/FA
 2/10/22  Kraig Biocraft Laboratories, Inc. S-1                   67:13M                                    M2 Compliance LLC/FA
12/03/21  Kraig Biocraft Laboratories, Inc. S-1/A                 64:13M                                    M2 Compliance LLC/FA
 8/25/21  Kraig Biocraft Laboratories, Inc. S-1/A                 63:12M                                    M2 Compliance LLC/FA
 5/26/21  Kraig Biocraft Laboratories, Inc. S-1/A                 86:9.3M                                   M2 Compliance LLC/FA
 4/15/21  Kraig Biocraft Laboratories, Inc. S-1/A                  1:74K                                    M2 Compliance LLC/FA
 4/14/21  Kraig Biocraft Laboratories, Inc. S-1/A                  2:161K                                   M2 Compliance LLC/FA
 4/05/21  Kraig Biocraft Laboratories, Inc. S-1                   63:6M                                     M2 Compliance LLC/FA
 3/12/21  Kraig Biocraft Laboratories, Inc. 10-K       12/31/20   67:5.7M                                   M2 Compliance LLC/FA
 2/18/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 2/08/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 8/24/20  Kraig Biocraft Laboratories, Inc. S-1/A                 68:7.8M                                   M2 Compliance LLC/FA
Top
Filing Submission 0001213900-08-000516   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 5:50:40.2am ET